Clinical Trials Logo

Clinical Trial Summary

In view of both endothelial injury in pre-eclampsia, high blood pressure and kidney impairment characteristics, a recent study demonstrated that the serum levels of NGAL increased at the end of the second trimester in women who subsequently developed pre-eclampsia compared to the control group.

This correlates well with the endothelial damage that occurs during pre-eclampsia and thus NGAL can be considered as a promising marker in predicting both early and late onset pre-eclampsia. It may be required to combine one or more biomarker with NGAL to increase the precision, and sensitivity for detection of risk and reliability of using biomarkers for pre-eclampsia.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02665897
Study type Observational
Source Assiut University
Contact
Status Completed
Phase N/A
Start date January 2016
Completion date May 2017